Thus, in cell types where AR regulation of ACE2 and TMPRSS2 does not exist, the broader transcriptional repression by BET inhibitors may block expression of these key host factors, and agents targeting BET proteins may have a different therapeutic efficacy in COVID-19 than direct AR inhibitors. The gene discussed is AR; the disease is COVID-19.